CYP19A1 and ovarian serous adenocarcinoma: Thus, this study investigates endocrine therapy with the aromatase inhibitor letrozole alone or in combination with established targeted therapies in the maintenance after first line treatment with cytoreductive surgery and adjuvant chemotherapy in high-grade serous ovarian cancer patients.